Press release
Care Solutions
April 16, 2024

in-cosmetics® global 2024: Evonik highlights growing biosolutions portfolio

  • Focus on biotech actives and eco-friendly biosurfactants 
  • Continuous expansion of botanical extracts and claim-substantiated natural actives 
  • Meeting demand for sustainable, science-based solutions

Evonik is presenting its latest innovations at the leading cosmetic tradeshow in-cosmetics global in Paris, 16-18 April, 2024. At this year’s show, Evonik will focus on its growing portfolio of biosolutions, including its sustainable biosurfactants and biotech actives.  

By expanding its range of biosolutions, Evonik is leveraging its biotechnology platform, which is part of the company’s life sciences division Nutrition & Care. The division uses biotechnology to create high-value system solutions that are driving Evonik’s transformation to become the preferred specialties partner to the cosmetics and personal care industry. 

“Our vision is driven by sustainability, inspired by innovation and defined by collaboration! With so many new innovations to present at this year’s show, I can truly say that we are living this vision,” said Johann-Caspar Gammelin, president of Evonik’s Nutrition & Care division. 

“We are committed to becoming the leading sustainable specialties partner to our industries, and we are energetically pursuing this goal through acquisitions, innovation, sustainability and service. I invite our customers and prospects to come and talk to us and find out how we can work together!” said Yann d'Hervé, head of Evonik's Care Solutions business line. 

Earlier this year, Evonik manufactured the first products from its new biosurfactants plant – the first in the world to produce rhamnolipids on an industrial scale. The official opening of this plant is planned for May 2024. Evonik’s biosurfactants are recognized for their exceptional sustainability credentials without compromising on performance and are already marketed in the personal care industry.  

Evonik’s biotech actives are also being featured prominently during the show. This year, Evonik is celebrating the 30th anniversary of the technology that enabled the production of pure, skin-identical ceramides. Three decades on, Evonik continues to innovate ceramides and sphingolipids, their biological pathways, and versatile claims. 

Following a series of successful acquisitions, Evonik is bringing together its expertise in a new business segment, Botanicals & Natural Actives. The new segment will enable the company to better meet the growing demand for botanical extracts and claim-substantiated natural actives.  

The company’s actives and cosmetic ingredients business is supported by the newly established Evonik Skin Institute, which provides customers with enhanced support for claim substantiated cosmetics. 

Evonik’s key innovation highlights at in-cosmetics global 2024 include: 

  • Glycolipid biosurfactants for personal hygiene products: RHEANCE® One and SOPHANCE® LA-A provide an eco-friendly solution for personal care products. These biosurfactants provide an effective and gentle cleansing experience while minimizing their impact on the aquatic environment.  
  • ECOHANCE® program to enhance the use of next generation feedstocks. ECOHANCE® Remo XP is a planet-friendly multifunctional rheology modifier for surfactant systems, which is manufactured by a low energy enzymatic process from alterative feedstocks. ECOHANCE® Soft Baobab oil is sourced responsibly in partnership with the UNCCD and certified by FairWild.  
  • Vegan collagen: Evonik markets Vecollage™ Fortify L, a vegan, skin-identical collagen produced from renewable feedstocks using a fermentation-based process. In cooperation with Jland Biotech, further biotech-based vegan collagens will be launched later this year.  
  • 30 years of ceramides: The latest addition to Evonik’s ceramides portfolio is HAIRMIMICS® Boost, which mimics essential lipids in the hair to support healthy, strong, resilient hair, offering high efficacy and containing traceable castor oil.  
  • Natural defense against body odor: new data prove 48-hour efficacy, microbiome modulation benefits and on-demand activity of Evonik’s portfolio of 100 percent natural, non-staining deodorant solutions such as dermosoft® decalact deo MB, and dermosoft G 3 CY MB TEGODEO® A30 eco.  

Detailed information on the above innovations is available at the Evonik Booth 1K30. During the show, Evonik is hosting a series of Customer Seminars on personalized beauty such as developing a cosmetic product, fluid skin care products, lamellar liquid crystal emulsions and more. Evonik is also presenting a Technical Seminar on glycolipid biosurfactants and giving a talk on the ECOHANCE® program in the Sustainability Zone. 

 

More information:

https://personal-care.evonik.com/en/events/in-cosmetics

COMPANY INFORMATION

Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €15.3 billion and an operating profit (adjusted EBITDA) of €1.66 billion in 2023. Evonik goes far beyond chemistry to create innovative, profitable, and sustainable solutions for customers. More than 33,000 employees work together for a common purpose: We want to improve life today and tomorrow.

ABOUT NUTRITION & CARE

The focus of the business of the Nutrition & Care division is on health and quality of life. It develops differentiated solutions for active pharmaceutical ingredients, medical devices, nutrition for humans and animals, personal care, cosmetics, and household cleaning. In these resilient end markets, the division generated sales of €3.61 billion in 2023 with more than 5,600 employees. 

DISCLAIMER

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.